Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc. (the Company), a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), ...
The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...
Beyond Efficacy: Cost and Resource Implications of First-Line Systemic Therapies for Metastatic Renal Cell Carcinoma Talquetamab is a G protein–coupled receptor class C group 5 member D ...
With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback